


Claims

1. A compound of formula (I)



5 a prodrug, *N*-oxide, addition salt, quaternary amine, metal complex or stereochemically isomeric form thereof wherein

Q is C_{1-6} alkyl optionally substituted with one or more substituents each independently selected from the group consisting of trifluoromethyl, C_{3-7} cycloalkyl, Ar^2 ,

hydroxy, C_{1-4} alkoxy, C_{1-4} alkylthio, Ar^2 -oxy-, Ar^2 -thio-, $Ar^2(CH_2)_n$ oxy,

10 $Ar^2(CH_2)_n$ thio, hydroxycarbonyl, aminocarbonyl, C_{1-4} alkylcarbonyl, Ar^2 carbonyl, C_{1-4} alkoxycarbonyl, $Ar^2(CH_2)_n$ carbonyl, aminocarbonyloxy, C_{1-4} alkylcarbonyloxy, Ar^2 carbonyloxy, $Ar^2(CH_2)_n$ carbonyloxy, C_{1-4} alkoxycarbonyl($CH_2)_n$ oxy, mono- or di(C_{1-4} alkyl)aminocarbonyl, mono- or di(C_{1-4} alkyl)aminocarbonyloxy, aminosulfonyl, mono- or di(C_{1-4} alkyl)aminosulfonyl or a heterocycle selected









15 from the group consisting of pyrrolidinyl, pyrrolyl, dihydropyrrolyl, imidazolyl, triazolyl, piperidinyl, homopiperidinyl, piperazinyl, pyridyl and tetrahydro-pyridyl, wherein each of said heterocycle may optionally be substituted with oxo or C_{1-6} alkyl; or **Q** is C_{1-6} alkyl substituted with two substituents wherein one substituent is selected from the group consisting of amino, mono- and di C_{1-4} alkyl-amino and Ar^2-C_{1-4} alkylamino and the other substituent is selected from the group consisting of carboxyl, C_{1-6} alkyloxycarbonyl, Ar^2-C_{1-4} alkyloxycarbonyl, aminocarbonyl and aminosulfonyl;

G is a direct bond or C_{1-10} alkanediyl optionally substituted with one or more substituents independently selected from the group consisting of hydroxy,

25 C_{1-6} alkyloxy, Ar^1C_{1-6} alkyloxy, C_{1-6} alkylthio, Ar^1C_{1-6} alkylthio, $HO(-CH_2-CH_2-O)_n$, C_{1-6} alkyloxy(- $CH_2-CH_2-O)_n$ and Ar^1C_{1-6} alkyloxy(- $CH_2-CH_2-O)_n$;

R¹ is Ar^1 or a monocyclic or bicyclic heterocycle being selected from piperidinyl, piperazinyl, pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, furanyl, tetrahydro-furanyl, thieryl, pyrrolyl, thiazolyl, oxazolyl, imidazolyl, isothiazolyl, pyrazolyl, isoazolyl, oxadiazolyl, quinolinyl, quinoxalinyl, benzofuranyl, benzothienyl, benzimidazolyl, benzoxazolyl, benzthiazolyl, pyridopyridyl, naphthiridinyl,

*1H-imidazo[4,5-b]pyridinyl, 3*H*-imidazo[4,5-b]pyridinyl, imidazo[1,2-a]-pyridinyl, 2,3-dihydro-1,4-dioxino[2,3-b]pyridyl or a radical of formula*



;

wherein each of said monocyclic or bicyclic heterocycles may optionally be substituted

- 5 with 1 or where possible more, such as 2, 3, 4 or 5, substituents individually selected from the group of substituents consisting of halo, hydroxy, amino, cyano, carboxyl, C₁₋₆alkyl, C₁₋₆alkyloxy, C₁₋₆alkylthio, C₁₋₆alkyloxyC₁₋₆alkyl, Ar¹, Ar¹C₁₋₆alkyl, Ar¹C₁₋₆alkyloxy, hydroxyC₁₋₆alkyl, mono-or di(C₁₋₆alkyl)amino, mono-or di(C₁₋₆alkyl)aminoC₁₋₆alkyl, polyhaloC₁₋₆alkyl, C₁₋₆alkylcarbonylamino, C₁₋₆alkyl-SO₂-NR^{4a}-, Ar¹-SO₂-NR^{4a}-, C₁₋₆alkyloxycarbonyl, -C(=O)-NR^{4a}R^{4b}, HO(-CH₂-CH₂-O)_n-, halo(-CH₂-CH₂-O)_n-, C₁₋₆alkyloxy(-CH₂-CH₂-O)_n-, Ar¹C₁₋₆alkyloxy(-CH₂-CH₂-O)_n- and mono-or di(C₁₋₆alkyl)amino(-CH₂-CH₂-O)_n-, each n independently is 1, 2, 3 or 4;
- 10 one of R^{2a} and R^{3a} is C₁₋₆alkyl and the other one of R^{2a} and R^{3a} is hydrogen; C₁₋₆alkyl; and R^{2b} is hydrogen or C₁₋₆alkyl, and R^{3b} is
- 15 in case R^{2a} is different from hydrogen then R^{2b} is hydrogen or C₁₋₆alkyl, and R^{3b} is hydrogen;
- 20 in case R^{3a} is different from hydrogen then R^{3b} is hydrogen or C₁₋₆alkyl, and R^{2b} is hydrogen; or R^{3b} is C₁₋₆alkyl; and R^{3a}, R^{2a}, R^{2b} all are hydrogen; or R^{2b} is C₁₋₆alkyl; and R^{3a}, R^{2a}, R^{3b} all are hydrogen; R^{4a} and R^{4b} can be the same or can be different relative to one another, and are each independently hydrogen or C₁₋₆alkyl; or

R^{4a} and R^{4b} taken together may form a bivalent radical of formula $-(CH_2)_s-$;

R^5 is hydrogen or C_{1-6} alkyl;

m is 1 or 2;

p is 1 or 2;


5 s is 4 or 5;

t is 1, 2 or 3;

Ar^1 is phenyl or phenyl substituted with 1 or more, such as 2, 3 or 4, substituents selected from halo, hydroxy, C_{1-6} alkyl, hydroxy C_{1-6} alkyl, polyhalo C_{1-6} alkyl, and C_{1-6} alkyloxy;


10 Ar^2 is phenyl or phenyl substituted with 1 or more, such as 2, 3 or 4, substituents selected from the group consisting of halo, hydroxy, amino, cyano, C_{1-6} alkyl, hydroxy C_{1-6} alkyl, polyhalo C_{1-6} alkyl, amino C_{1-6} alkyl, C_{1-6} alkyloxy, amino-sulfonyl, aminocarbonyl, hydroxycarbonyl, C_{1-4} alkylcarbonyl, mono- or di(C_{1-4} alkyl)amino, mono- or di(C_{1-4} alkyl)aminocarbonyl, mono- or di(C_{1-4} alkyl)aminosulfonyl, mono- or di(C_{1-4} alkyl)amino C_{1-6} alkyl and C_{1-4} alkoxycarbonyl.

2. A compound as claimed in claim 1, wherein the compound has the formula




20 wherein Q , t , R^5 , G and R^1 are as claimed in claim 1; and
 R^{2a} is C_{1-6} alkyl;
 R^{2b} is hydrogen or C_{1-6} alkyl.

3. A compound as claimed in claim 1, wherein the compound has the formula



25 wherein Q , t , R^5 , G and R^1 are as claimed in claim 1; and
 R^{3a} is C_{1-6} alkyl;
 R^{3b} is hydrogen or C_{1-6} alkyl.


4. A compound as claimed in claim 1, wherein the compound has the formula



wherein Q, t, R⁵, G and R¹ are as claimed in claim 1; and
R^{3b} is C₁₋₆alkyl.

5

5. A compound as claimed in any of claims 1 to 4 wherein t is 2.
6. A compound as claimed in any of claims 1 to 5 wherein G is C₁₋₁₀alkanediyl.
- 10 7. A compound according to in any of claims 1 - 5, wherein G is methylene.
8. A compound according to any of claims 1 - 7, wherein R¹ is pyridyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of halo, hydroxy, amino, cyano, carboxyl, C₁₋₆alkyl, C₁₋₆alkyloxy, C₁₋₆alkylthio, C₁₋₆alkyloxyC₁₋₆alkyl, Ar¹, Ar¹C₁₋₆alkyl, Ar¹C₁₋₆alkyloxy, hydroxyC₁₋₆alkyl, mono-or di(C₁₋₆alkyl)amino, mono-or di(C₁₋₆alkyl)amino-C₁₋₆alkyl, polyhaloC₁₋₆alkyl, C₁₋₆alkylcarbonylamino, C₁₋₆alkyl-SO₂-NR^{4a}-, Ar¹-SO₂-NR^{4a}-, C₁₋₆alkyloxycarbonyl, -C(=O)-NR^{4a}R^{4b}, HO(-CH₂-CH₂-O)_n-, halo(-CH₂-CH₂-O)_n-, C₁₋₆alkyloxy(-CH₂-CH₂-O)_n-, Ar¹C₁₋₆alkyloxy(-CH₂-CH₂-O)_n- and mono-or di(C₁₋₆alkyl)amino(-CH₂-CH₂-O)_n-.
- 15 9. A compound according to any of claims 1 - 7, wherein R¹ is pyridyl substituted with 1 or 2 substituents independently selected from the group consisting of hydroxy and C₁₋₆alkyl.
- 20 10. A compound according to any of claims 1 - 7, wherein R¹ is Ar¹, quinolinyl, benzimidazolyl, a radical of formula




- 25 or pyrazinyl; wherein each of the radicals Ar¹, quinolinyl, benzimidazolyl, (c-4), or pyrazinyl may optionally be substituted with the substituents of said radicals as claimed in claim 1.

11. A compound according to any of claims 1 - 7, wherein R¹ is phenyl optionally substituted with one, two or three radicals selected from the group consisting of halo, hydroxy, C₁₋₆alkyl, C₁₋₆alkyloxy; quinolinyl; a radical (c-4) wherein m is 2, 5 optionally substituted with up to two radicals selected from C₁₋₆alkyl; benzimidazolyl optionally substituted with C₁₋₆alkyl; pyrazinyl optionally substituted with up to three radicals selected from C₁₋₆alkyl.
12. A compound according to any of claims 1 - 11, wherein R⁵ is hydrogen.
- 10 13. A compound according to any of claims 1 - 12, wherein Q is C₁₋₆alkyl optionally substituted with one or two substituents each independently selected from trifluoromethyl, C₃₋₇cycloalkyl, Ar², hydroxy, C₁₋₄alkoxy, Ar²-oxy-, Ar²(CH₂)_noxy, hydroxycarbonyl, aminocarbonyl, C₁₋₄alkylcarbonyl, C₁₋₄alkoxy-carbonyl, aminocarbonyloxy, Ar²(CH₂)_ncarbonyloxy, C₁₋₄alkoxycarbonyl-(CH₂)_noxy, mono- or di(C₁₋₄alkyl)aminocarbonyl, aminosulfonyl, mono- or di(C₁₋₄alkyl)aminosulfonyl or a heterocycle selected from pyrrolidinyl, pyrrolyl, dihydropyrrolyl, imidazolyl, triazolyl, piperidinyl, homopiperidinyl, piperazinyl and tetrahydropyridyl, wherein each of said heterocycle may optionally be 15 substituted with oxo or C₁₋₆alkyl; or Q is C₁₋₆alkyl substituted with two substituents wherein one substituent is selected from amino and the other substituent is selected from carboxyl and C₁₋₆alkyloxycarbonyl;
- 20 14. A compound according to any of claims 1 - 12, wherein Q is C₁₋₆alkyl optionally substituted with one or two substituents each independently selected from aminocarbonyl, C₁₋₄alkoxycarbonyl, aminocarbonyloxy, Ar²(CH₂)_ncarbonyloxy, mono- or di(C₁₋₄alkyl)aminocarbonyl, aminosulfonyl, mono- or di(C₁₋₄alkyl)aminosulfonyl, pyrrolidinyl, dihydropyrrolyl, piperidinyl, homopiperidinyl and tetrahydropyridyl; or Q is C₁₋₆alkyl substituted with two 25 substituents wherein one substituent is amino and the other substituent is selected from carboxyl and C₁₋₆alkyloxycarbonyl.
- 30 15. A compound according to any of claims 1 - 12, wherein Q is C₁₋₆alkyl optionally substituted with one substituent selected from aminocarbonyl, C₁₋₄alkoxy-carbonyl, aminocarbonyloxy, Ar²(CH₂)_ncarbonyloxy, mono- or di(C₁₋₄alkyl)-aminocarbonyl, aminosulfonyl, mono- or di(C₁₋₄alkyl)aminosulfonyl, pyrrolidinyl, dihydropyrrolyl, piperidinyl, homopiperidinyl and tetrahydropyridyl, and optionally with a second substituent which is hydroxy or Q is C₁₋₆alkyl 35


substituted with two substituents wherein one substituent is amino and the other substituent is selected from carboxyl and C₁₋₆alkyloxycarbonyl.

- 16. A compound according to any of claims 1 - 12, wherein Q is C₁₋₆alkyl substituted with aminocarbonyl, C₁₋₄alkoxycarbonyl, aminocarbonyloxy, mono- or di(C₁₋₄alkyl)aminocarbonyl, aminosulfonyl, mono- or di(C₁₋₄alkyl)aminosulfonyl, pyrrolidinyl, dihydropyrrolyl, piperidinyl, homopiperidinyl or tetrahydropyridyl.
- 5 17. A compound as claimed in any one of claims 1 to 16 for use as a medicine.
- 10 18. A pharmaceutical composition comprising a pharmaceutically acceptable carrier, and as active ingredient a therapeutically effective amount of a compound as claimed in any one of claims 1 to 16.
- 15 19. A process for preparing a pharmaceutical composition as claimed in claim 18, said process comprising intimately mixing a pharmaceutically acceptable carrier with a therapeutically effective amount of a compound as claimed in any one of claims 1 to 16.
- 20 20. The use of a compound as claimed in any of claims 1 to 16 for the manufacture of a medicament for inhibiting RSV replication.
- 21. A process for preparing a compound as claimed in any of claims 1 to 23, said process comprising
 - 25 (a) reacting an intermediate of formula (II) with a reagent (III) as in the following reaction scheme:



- (b) reacting an intermediate of formula (IV) with a reagent (V) as in the following reaction scheme:

-47-



wherein Q, G, t, R¹, R^{2a}, R^{2b}, R^{3a}, R^{3b}, R⁵ are as claimed in any of claims 1 to 16; and optionally converting the thus obtained compounds of formula (I) into their pharmaceutically acceptable base-addition or acid addition salt form by treatment with a suitable base or acid and conversely treating the base-addition or acid addition salt form with an acid or a base to obtain the free form of the compound of formula (I).